---
title: 'Sr. Manager - IT at Genetix Biotherapeutics'
canonical: 'https://feeny.ai/job/sr-manager-it-genetix-biotherapeutics-somerville-cvc32vn94f3b'
type: 'job'
last_seen: '2026-11-02'
---

# Sr. Manager - IT at Genetix Biotherapeutics

- **Company:** Genetix Biotherapeutics
- **Location:** Somerville, MA
- **Compensation:** $170k–$185k
- **Posted:** 2026-10-26
- **Last confirmed live:** 2026-11-02
- **Apply:** https://job-boards.greenhouse.io/genetixbiotherapeutics/jobs/8324674

## Job description

## About Genetix Biotherapeutics

At Genetix Biotherapeutics every role has meaning, every team member is respected, and every day is a chance to make a difference. When you join Genetix, you're not just landing a new role, you become part of a company that's pursuing curative gene therapies to give patients and their families more days. We are doers, thinkers and collaborators who embrace and live by our values:

Our innovation is rooted in the diversity of our teams and results are achieved through cooperation and the integration of multiple viewpoints. This is personal and we approach every challenge with radical care.

This role is based in Somerville, MA and follows a hybrid schedule of three days onsite per week.

To support regular in-office collaboration, only candidates within commuting distance of Somerville will be considered.

Position Summary

The Senior Manager, IT owns the day-to-day delivery of the security and infrastructure services that support Genetix’s commercial products. You will lead identity, endpoint, backup and recovery, network, and cloud operations during a period of active modernization, including a move of identity services toward Microsoft Entra, a rebuild of backup and DR, and hardening of both corporate and laboratory environments. This is a hands-on leader who can run projects through change control in a validated, regulated environment, manage vendors, and build a team and operating rhythm that is secure, auditable, and reliable.

## RESPONSIBILITIES

Identity & Access

- Lead identity modernization across Microsoft Entra ID, Okta, and hybrid Active Directory, including SSO migrations for business applications, conditional access, MFA coverage, and authentication policy.
- Own privileged access: PIM, admin role reduction, service account de-privileging and lifecycle (inventory, owner, expiry, rotation), and stale account cleanup.
- Run access governance and least-privilege role design for business applications, with timely provisioning and deprovisioning for employees, contractors, consultants, and managed service providers.
- Own the AD security backlog, directory sync health (Entra Connect), and Group Policy migration to Intune.

Infrastructure, Backup & Cloud

- Operate core infrastructure: AWS (multi-account, federated access, networking), on-prem and virtualized servers, firewalls and VPN, and legacy file services.
- Build and run backup and recovery, including backup platform deployment, network paths to cloud targets, restore testing, retention, and data archiving.
- Lead patching and lifecycle: OS and application patching, server and client end-of-life, and scheduled outage coordination.
- Manage DNS and domain hygiene, including verification records, decommissioned records, and legacy domain consolidation, to reduce attack surface.
- Lead monitoring and observability, including tool replacement and alerting tied to incident response.

Endpoint, Lab & Security Operations

- Own endpoint and lab security: disk encryption and Secure Boot compliance, endpoint management, DNS-layer protection, patch policy for lab and corporate systems, and removal of retired tools.
- Own intake and triage of security reports, including phishing submissions and external vulnerability disclosures, with defined response and closure.
- Support audits and customer or partner security assessments (GxP, 21 CFR Part 11, SOX, SOC 2), including questionnaires, evidence collection, and remediation tracking.

Validated Systems & Change Control

- Partner with Quality and application owners on infrastructure for validated systems (LIMS/ELN, statistical computing, lab instruments), including server builds, security hot fixes, non-production testing, regression sign-off, and change control.
- Support commercial and partner-facing systems and treatment center security and connectivity requirements.

## Team, Vendors & Delivery

- Lead, coach, and develop engineers and analysts; set priorities and manage workload across projects and service requests.
- Manage managed service providers and vendors (SLAs, contracts, performance, escalation).
- Define SLAs and reporting for security and infrastructure requests, and improve intake, approval, and onboarding workflows with the service desk.
- Write runbooks, SOPs, and change records so operations are repeatable and audit-ready.
- Apply AI tools such as Claude in daily work, including integrations with enterprise systems, and champion responsible AI adoption with appropriate access controls.

## QUALIFICATIONS

Required

- Bachelor’s degree in IT, Computer Science, Information Security, or a related field, or equivalent practical experience.
- 8+ years in IT infrastructure, security operations, or systems engineering, including 3+ years leading people or technical teams.
- Hands-on identity experience: Entra ID and hybrid Active Directory required; Okta or another SSO platform strongly preferred. Includes conditional access, MFA, PIM, and service account governance.
- Hands-on experience with endpoint management (Intune), disk encryption, patching, and vulnerability management.
- Experience with backup and recovery platforms, cloud networking (AWS preferred), firewalls and VPN, and Microsoft 365.
- Experience managing projects through formal change control and managing vendors.
- Experience supporting audits or compliance programs in a regulated environment.
- Working knowledge of AI tools such as Claude (or similar) applied to operations.
- Strong communication skills, risk-based decision making, and the ability to prioritize competing demands in a small, fast-moving team.

## Preferred

- Biotech, pharma, or GxP experience, including computer system validation and supporting lab systems and instrumentation.
- Experience modernizing hybrid environments (IdP migrations, GPO to Intune, monitoring replacement, legacy domain consolidation).
- Security or infrastructure certifications (e.g., CISSP, CISM, Security+, AWS Security Specialty, Microsoft identity/security certifications).
- Experience in a company that is rebuilding or scaling its IT function.

Additional Information

The pay transparency range provided below is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting. We may ultimately pay more or less than the posted range, and the range may be modified in the future. This role is eligible for an annual bonus and long-term incentive. Actual base salary pay will be based on several factors, including but not limited to experience, skills, relevant education/qualifications, external market, internal equity, and other job-related factors permitted by law.

Genetix’s total rewards package also provides employees with a comprehensive and competitive benefits suite to support a variety of employee needs. These benefits include comprehensive health, life and disability insurance, employer-matched 401(k) plan, lifestyle spending account, flexible time-off + paid holidays and winter holiday period, tuition reimbursement & loan repayment assistance, paid parental leave, paid onsite parking, commuter subsidy, and much more.

Pay Transparency $170,000—$185,000 USD

Genetix is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, veteran status or any other applicable legally protected characteristics.

## About Genetix Biotherapeutics

## Company Overview
- **One-liner**: Genetix Biotherapeutics (formerly bluebird bio) is a commercial-stage biotechnology company dedicated to developing and delivering one-time, curative genetic therapies for patients with severe rare genetic diseases.
- **Entity Type**: Private (taken private in June 2025 after a sale to new ownership)
- **Headquarters**: Somerville, Massachusetts, USA (with a presence in the Netherlands)
- **Founded**: 1992 (founded as Genetix Pharmaceuticals; rebranded to bluebird bio in 2010; rebranded back to Genetix Biotherapeutics in September 2025)
- **Founders**: Not publicly disclosed; the company was originally founded as Genetix Pharmaceuticals in 1992.

## Core Business
- **Primary Industries**: Biotechnology, Gene Therapy, Rare Disease Therapeutics
- **Target Customers**: B2B (healthcare providers, qualified treatment centers, payers/insurers) and B2C (patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy)
- **Mission**: "To transform lives through curative therapies for patients with rare, genetic diseases."

## Products & Services
- **LYFGENIA™ (lovotibeglogene autotemcel / lovo-cel)**: An FDA-approved, one-time gene therapy for patients 12 years and older with sickle cell disease. It works by adding functional copies of a modified β-globin gene into the patient's own blood stem cells.
- **ZYNTEGLO™ (betibeglogene autotemcel)**: An FDA-approved, one-time gene therapy for patients with β-thalassemia who require regular blood transfusions. It adds functional copies of a modified β-globin gene into the patient's own blood stem cells.
- **SKYSONA™ (elivaldogene autotemcel)**: An FDA-approved, one-time gene therapy for boys with cerebral adrenoleukodystrophy (CALD), a rare, progressive genetic brain disease. It adds a functional copy of the ABCD1 gene into the patient's own blood stem cells.
- **Patient Support Program**: Personalized assistance for patients and families navigating the treatment journey, including insurance questions, treatment center coordination, and one-on-one support.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed (privately held after take-private transaction in June 2025)
- **Key Metrics**:
  - **Annual Revenue**: Not publicly disclosed (but the company reported strong revenue growth in 2025 and achieved its **first ever profitable quarter** in that year)
  - **Total Funding**: Not publicly disclosed (new investors provided "significant capital" to support operational objectives following the take-private transaction)
- **Notable Investors/Partners**: New ownership group (undisclosed); manufacturing partners include **Minaris**, **Lonza**, and **MilliporeSigma** (the U.S. and Canada business of Merck KGaA, Darmstadt, Germany)
- **Growth Signals**:
  - **2025 commercial performance**: >100 patients treated in the U.S.; >150 patients completed their first cell collection cycle; 70 active Qualified Treatment Centers (QTCs) — the largest network for hemoglobinopathy gene therapies nationwide
  - **2026 outlook**: Doubling manufacturing capacity by mid-2026; targeting first full year of profitability; expanding LYFGENIA label to pediatric patients <12 years of age; advancing cryopreserved apheresis to improve the treatment experience

## Competitive Advantages
- **First-mover & market leader**: The only company with FDA approval for three gene therapies, and the market leader in the U.S. for hemoglobinopathy gene therapies
- **Proven commercial model**: >100 patients treated in a single year demonstrates real-world commercial execution and manufacturing scale
- **Decades of scientific innovation**: Over 30 years of R&D in genetic therapy, with extensive clinical data from hundreds of treated patients (including 15-year long-term follow-up studies)
- **Strong access**: LYFGENIA and ZYNTEGLO have meaningful access for >90% of eligible patients with commercial or Medicaid coverage
- **One-time curative approach**: Therapies are designed to treat the underlying cause of disease, offering durable, potentially life-long benefits from a single administration

## Strategic Focus
- **Commercial execution & patient access**: Expanding the Qualified Treatment Center network and making the treatment journey simpler for patients and providers
- **Manufacturing scale-up**: Doubling manufacturing capacity in 2026 through partnerships with CDMOs to meet growing patient demand
- **Process optimization**: Implementing cryopreserved apheresis to improve the patient and provider experience
- **Label expansion**: Advancing the HGB-210 Phase 3 study to bring LYFGENIA to pediatric sickle cell patients under 12 years of age
- **Full-year profitability**: Targeting the company's first full year of profitability in 2026

## Why Work Here
- **Mission-driven culture**: "United by purpose" — the company is laser-focused on transforming the lives of patients with rare, genetic diseases through curative therapies
- **Strong momentum**: Recently achieved first-ever profitable quarter, with rapid commercial growth and a clear plan for expansion in 2026
- **Remote/hybrid policy**: Roles are listed as both on-site (Somerville, MA) and remote (e.g., Account Manager, Gene Therapy) — flexible arrangements appear available depending on the role
- **Active hiring**: 23 job postings as of the search date, spanning Commercial, Quality Assurance, Technical Operations, Medical, and Regulatory functions
- **Experienced leadership**: Led by CEO David Meek (ex-Mirati Therapeutics, Ipsen) with a seasoned executive team of industry veterans, signaling strong strategic direction
- **Notable perks/culture**: High-impact work at the intersection of cutting-edge science and commercial execution; opportunity to join a company in the middle of a dramatic turnaround and growth phase; patient-centric focus with a dedicated support program

## Sources
1. [genetixbiotx.com - Company website](https://www.genetixbiotx.com/)
2. [job-boards.greenhouse.io - Careers page](http://job-boards.greenhouse.io/genetixbiotherapeutics)
3. [linkedin.com - LinkedIn company page](https://www.linkedin.com/company/genetix-biotherapeutics)
4. [genetixbiotx.com - Press release: Rebrand from bluebird bio](https://www.genetixbiotx.com/press-release-2025-09-18.html)
5. [genetixbiotx.com - Press release: 2025 commercial results & 2026 priorities](https://www.genetixbiotx.com/press-release-2026-03-02.html)

## Other roles at Genetix Biotherapeutics

- [Sr. Manager, LVV Manufacturing](https://feeny.ai/job/sr-manager-lvv-manufacturing-genetix-biotherapeutics-somerville-z0yp801tagkj) — Somerville, MA
- [National Account Executive, West](https://feeny.ai/job/national-account-executive-west-genetix-biotherapeutics-los-angeles-5j8hdvsqn5cg) — Los Angeles, CA
- [Director, Pricing, Payer Contracting & Analytics](https://feeny.ai/job/director-pricing-payer-contracting-analytics-genetix-biotherapeutics-somerville-qv5w015kka01) — Somerville, MA
- [Sr. Director, Quality Operations](https://feeny.ai/job/sr-director-quality-operations-genetix-biotherapeutics-somerville-traazwk35kj1) — Somerville, MA
- [Senior Manager, Quality Assurance Vendor & Audit Management](https://feeny.ai/job/senior-manager-quality-assurance-vendor-audit-management-genetix-sn50jbp7ge60) — Somerville, MA
- [Process Engineer II](https://feeny.ai/job/process-engineer-ii-genetix-biotherapeutics-somerville-jtx6w2g8h780) — Somerville, MA
- [Sr. Manager - IT Commercial and Medical Systems](https://feeny.ai/job/sr-manager-it-commercial-and-medical-systems-genetix-biotherapeutics-somerville-drs30kf4perv) — Somerville, MA
- [Sr. Director, Regulatory Strategy](https://feeny.ai/job/sr-director-regulatory-strategy-genetix-biotherapeutics-somerville-fpj4qjceza7s) — Somerville, MA
- [Manager, End User Services & Lab Support](https://feeny.ai/job/manager-end-user-services-lab-support-genetix-biotherapeutics-somerville-q2ah951d4k1c) — Somerville, MA
- [Paralegal and Legal & Compliance Operations Manager](https://feeny.ai/job/paralegal-and-legal-compliance-operations-manager-genetix-biotherapeutics-m768zfn33tct) — Somerville, MA